← Evidence map

TrialTargeted oncology2026

Phase I/II Study of the CDK2/9 Inhibitor Fadraciclib in Combination with Chemotherapy in Children with Advanced Malignancies: Arm K of the AcSé-ESMART Trial.

Alba Rubio-San-Simón et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Phase I/II Study of the CDK2/9 Inhibitor Fadraciclib in Combination with Chemotherapy in Children with Advanced Malignancies: Arm K of the AcSé-ESMART Trial. | OpenQuestion